Stockscreener 앱 받기
68.12
1.95%
1.30
시간 외 거래:
68.12
전일 마감가:
$66.82
열려 있는:
$67.17
하루 거래량:
230.64K
Relative Volume:
0.44
시가총액:
$2.60B
수익:
-
순이익/손실:
$-212.18M
주가수익비율:
-11.37
EPS:
-5.9897
순현금흐름:
$-181.33M
1주 성능:
+6.32%
1개월 성능:
-1.06%
6개월 성능:
-27.34%
1년 성능:
+43.80%
1일 변동 폭
$66.24
$68.41
1주일 범위
$64.01
$69.31
52주 변동 폭
$40.00
$99.50
Disc Medicine Inc Stock (IRON) Company Profile
명칭
Disc Medicine Inc
전화
(617) 674-9274
주소
321 ARSENAL STREET, SUITE 101, WATERTOWN
Compare IRON vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
IRON
Disc Medicine Inc
|
68.12 | 2.55B | 0 | -212.18M | -181.33M | -5.9897 |
VRTX
Vertex Pharmaceuticals Inc
|
435.93 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.62 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
808.43 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.50 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.89 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Disc Medicine Inc Stock (IRON) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-11-03 | 재개 | Stifel | Buy |
| 2025-07-21 | 개시 | Truist | Buy |
| 2025-07-03 | 재개 | Morgan Stanley | Overweight |
| 2025-06-11 | 재개 | Raymond James | Strong Buy |
| 2025-02-27 | 개시 | TD Cowen | Buy |
| 2024-11-05 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2024-11-04 | 업그레이드 | Raymond James | Outperform → Strong Buy |
| 2024-10-23 | 개시 | Jefferies | Buy |
| 2024-10-16 | 개시 | Scotiabank | Sector Outperform |
| 2024-08-22 | 개시 | Wells Fargo | Overweight |
| 2024-04-01 | 다운그레이드 | Raymond James | Strong Buy → Outperform |
| 2023-12-19 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2023-06-09 | 업그레이드 | Raymond James | Outperform → Strong Buy |
| 2023-06-07 | 개시 | H.C. Wainwright | Buy |
| 2023-05-17 | 개시 | Raymond James | Outperform |
| 2023-04-28 | 개시 | Cantor Fitzgerald | Overweight |
| 2023-04-21 | 개시 | Stifel | Buy |
| 2023-04-20 | 개시 | Morgan Stanley | Overweight |
| 2023-03-23 | 개시 | BMO Capital Markets | Outperform |
| 2023-02-28 | 개시 | SVB Securities | Outperform |
모두보기
Disc Medicine Inc 주식(IRON)의 최신 뉴스
Disc Medicine Eyes Mid-2026 Bitopertin Approval as EPP Trial Demand Surges - Yahoo Finance
Class action lawsuit launched over Disc Medicine's FDA drug rejection causing 22% stock drop - Pluang
IRON Investor News: If You Have Suffered Losses in Disc Medicine, Inc. (NASDAQ: IRON), You Are ... - Caledonian Record
IRON Investor News: If You Have Suffered Losses in Disc - GlobeNewswire
Why (IRON) Price Action Is Critical for Tactical Trading - Stock Traders Daily
Eagle Health Investments LP Purchases Shares of 27,100 Disc Medicine, Inc. $IRON - MarketBeat
Disc Medicine faces class action after FDA rejects drug application, stock drops 22%. - Pluang
IRON: APOLLO study enrollment exceeded targets, signaling high demand and unmet need for EPP therapies - TradingView
DNB Asset Management AS Raises Stock Holdings in Disc Medicine, Inc. $IRON - MarketBeat
First Light Asset Management, LLC's Disc Medicine Inc(IRON) Holding History - GuruFocus
Rosen Law Firm Encourages Disc Medicine, Inc. Investors to Inqui - GuruFocus
Disc Medicine faces class action after FDA rejects drug application, stock drops 22% - Pluang
Rosen Law Firm Encourages Disc Medicine, Inc. Investors to Inquire About Securities Class Action InvestigationIRON - The Norfolk Daily News
UBS Group AG Reduces Holdings in Disc Medicine, Inc. $IRON - MarketBeat
Should Disc Medicine’s RALLY-MF Data and Wider Pipeline Reveal a Pivotal Inflection for IRON’s Narrative? - simplywall.st
Disc Medicine, Inc.Common Stock (NQ: IRON - FinancialContent
IRON Maintained by Morgan Stanley -- Price Target Raised to $80. - GuruFocus
Cantor Fitzgerald Remains a Buy on Disc Medicine (IRON) - The Globe and Mail
Morgan Stanley Raises Price Target on Disc Medicine to $80 From $75, Keeps Overweight Rating - marketscreener.com
Understanding Momentum Shifts in (IRON) - Stock Traders Daily
IRON Investor News: If You Have Suffered Losses in Disc Medicine, Inc. (NASDAQ: IRON), You Are Encouraged to Contact The Rosen Law Firm About Your Rights - GlobeNewswire Inc.
Disc Medicine, Inc. Announces Oral Presentation of Phase 2 RALLY-MF Trial Data for DISC-0974 at EHA 2026 Congress and Corporate Update Call - Quiver Quantitative
Experimental anemia treatment shows 70% response in myelofibrosis trial - Stock Titan
Vanguard Group Inc. Acquires 319,621 Shares of Disc Medicine, Inc. $IRON - MarketBeat
Disc Medicine to present multiple hematology tr... | Pluang – Crypto, Stocks, Gold & Funds - Pluang
Stifel Maintains Disc Medicine(IRON.US) With Buy Rating, Maintains Target Price $111 - Moomoo
Hear Disc Medicine leaders in two live investor conference webcasts - Stock Titan
Disc Medicine to Participate in Upcoming Investor Conferences - FinancialContent
Number of shareholders of Disc Medicine, Inc. – NASDAQ:IRON - TradingView
Press releases provided by CNW - Techaeris
A Look At Disc Medicine (IRON) Valuation As Key APOLLO Phase 3 And Pipeline Milestones Progress - Sahm
Disc Medicine, Inc. (IRON) Eps Diluted (TTM) - Zacks Investment Research
HC Wainwright Cuts Earnings Estimates for Disc Medicine - MarketBeat
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Disc Medicine, Inc.IRON - PR Newswire
Disc Medicine FY2030 EPS Forecast Raised by HC Wainwright - MarketBeat
H.C. Wainwright Maintains Disc Medicine(IRON.US) With Buy Rating, Maintains Target Price $118 - Moomoo
Disc Medicine (IRON) Receives a Buy from H.C. Wainwright - The Globe and Mail
BMO Capital Maintains Disc Medicine(IRON.US) With Buy Rating, Maintains Target Price $100 - Moomoo
Truist Financial Maintains Disc Medicine(IRON.US) With Buy Rating, Maintains Target Price $83 - Moomoo
A Look At Disc Medicine (IRON) Valuation After Legal Probes And FDA Complete Response Letter - Yahoo Finance
Disc Medicine Q1 Net Loss Widens - Moomoo
Disc Medicine (NASDAQ:IRON) Releases Quarterly Earnings Results, Misses Estimates By $0.03 EPS - MarketBeat
Earnings Flash (IRON) Disc Medicine Posts Q1 Net Loss $1.65 a Share, vs. FactSet Est of $1.65 Loss - marketscreener.com
Disc Medicine (NASDAQ: IRON) posts wider Q1 loss but holds $730M cash - Stock Titan
Disc Medicine 1Q 2026: Net income $(63.5M), EPS $(1.65) — 10-Q Summary - TradingView
Earnings Flash (IRON) Disc Medicine Posts Q1 Net Loss $1.65 a Share, Vs. FactSet Est of $1.65 Loss - Moomoo
IRON: Phase 3 bitopertin trial enrollment completed; strong cash position supports pipeline into 2029 - TradingView
Disc Medicine finishes Phase 3 rare-disease trial, eyes Q4 data - Stock Titan
IRON: Net loss widened to $63.5M in Q1 2026 as bitopertin's FDA review was delayed for more data - TradingView
Disc Medicine (NASDAQ: IRON) posts Q1 2026 loss and advances late-stage trials - Stock Titan
Disc Medicine | 8-K: Disc Medicine Reports First Quarter 2026 Financial Results and Provides Business Update - Moomoo
Disc Medicine Inc (IRON) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.98%
0.12%
자본화:
|
볼륨(24시간):